EXCLI Journal Logo

EXCLI Journal publishes original research reports, authoritative reviews and case reports of experimental and clinical sciences.

EXCLI Journal (eISSN 1611-2156) is particularly keen to keep a broad view of science and technology, and therefore welcomes papers which bridge disciplines and may not suit the narrow specialism of other journals. Although the general emphasis is on biological sciences, studies from the following fields are explicitly encouraged:

Immunology, toxicology, ergonomics, neurosciences, psychology, occupational medicine, clinical and preclinical studies, drug development, pharmacology, environmental health, chemistry including analytical chemistry, biochemistry, cell biology, genetics, forensic medicine, oncology and cancer research, proteomics, systems biology, hepatology and gastroenterology, aging research, psychiatric research, behavioral sciences.

Mandatory metadata

2021-10-19

Since June 2021, ORCID* is mandatory for all authors when submitting to EXCLI Journal. It is desirable that the ORCID contains the (current) institution as minimum information, so that each author can be clearly assigned via the ORCID in the metadata.

If ORCID, addresses or e-mail addresses are missing or incorrect, we reserve the right to reject such submissions due to formal errors.

*ORCID (Open Researcher and Contributor ID) should speed up the submission process. This unique identifier for authors is included as a mandatory field for all contributors in the submission tool.

New Impact Factor

2021-07-01

Excli Journal Impact Factor 2020 increased to 4.068 and 73.66% JIF percentile in the Biology Sci category.

The Immediacy Index jumped to 1.596. EXCLI Journal is rapidly attracting citations.

A big thank you to all authors and contributors, reviewers and the EXCLI team! Only together this is possible!

Vol. 20 (2021)

Published continuously

Published: 2021-01-04

Molecular interaction of inhibitors with human brain butyrylcholinesterase

Authors: Shazi Shakil
Pages: 1597-1607
Published: 2021-11-25
Issue: Vol. 20 (2021)

Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells

Authors: Wojciech A. Cieślikowski, Tobias Haber, Slavomir Krajnak, Katharina Anic, Annette Hasenburg, Rene Mager, Joachim W. Thüroff, Walburgis Brenner
Pages: 1585-1596
Published: 2021-11-19
Issue: Vol. 20 (2021)

Toxic heavy metal concentrations in multiple sclerosis patients

A systematic review and meta-analysis

Authors: Sorour Sarihi, Maryam Niknam, Sanaz Mahjour, Mahnaz Hosseini-Bensenjan, Fatemeh Moazzen, Sahar Soltanabadi, Hamed Akbari
Pages: 1571-1584
Published: 2021-11-19
Issue: Vol. 20 (2021)

An update of advanced nanoplatforms for Glioblastoma Multiforme Management

Authors: Mariana Amaral, Nuno Cruz, Ana Rosa, Beatriz Nogueira, Diana Costa, Francisco Santos, Mariana Brazão, Pedro Policarpo, Rita Mateus, Yan Kobozev, Catarina Pinto Reis
Pages: 1544-1570
Published: 2021-11-15
Issue: Vol. 20 (2021)

Raynaud’s phenomenon in a drummer player

Microvascular disorder and nailfold video capillaroscopic findings

Authors: Maria Maddalena Sirufo, Alessandra Catalogna, Francesca De Pietro, Lia Ginaldi, Massimo De Martinis
Pages: 1526-1531
Published: 2021-10-28
Issue: Vol. 20 (2021)

A case of xenon inhalation therapy for respiratory failure and neuropsychiatric disorders associated with COVID-19

Authors: Vladimir Vasil'evich Udut, Sergei Alexandrovich Naumov, Diana Nikolaevna Evtushenko, Elena Vladimirovna Udut, Sergei Sergeevich Naumov, Gleb Nikolaevich Zyuz'kov
Pages: 1517-1525
Published: 2021-10-28
Issue: Vol. 20 (2021)

The eosinophilic variant of chronic myeloid leukemia

Authors: Stephen E. Langabeer
Pages: 1608-1609
Published: 2021-11-26
Issue: Vol. 20 (2021)

Sex ratio at birth in COVID-19 era

a report from Iran

Authors: Mostafa Saadat
Pages: 1499-1501
Published: 2021-10-13
Issue: Vol. 20 (2021)
View all articles from this issue
View All Issues